Business Context and Reporting Period
SpyGlass Pharma, Inc. (SGP) is a late-stage biopharmaceutical company developing the BIM-IOL System, a drug delivery device for glaucoma treatment. This Form 10-Q covers the quarterly period ended March 31, 2026. During this period, the Company completed its Initial Public Offering (IPO) on February 9, 2026, and executed a 1-for-5.7329 reverse stock split effective January 28, 2026. All outstanding redeemable convertible preferred stock converted to common stock in connection with the IPO.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(13.8) million | $(8.8) million |
| Operating Expenses | $15.4 million | $7.4 million |
| Research & Development (R&D) | $8.5 million | $6.1 million |
| General & Administrative (G&A) | $6.9 million | $1.4 million |
| Cash Used in Operating Activities | $(13.5) million | $(8.2) million |
| Cash Provided by Financing Activities | $157.8 million | $50.1 million |
| Cash and Cash Equivalents (End of Period) | $238.9 million | $58.0 million |
| Total Assets | $258.4 million | $115.9 million |
| Accumulated Deficit | $(118.5) million | $(73.7) million |
Material Changes vs. Prior Period
- Liquidity Transformation: Cash and cash equivalents increased from $96.4 million at year-end 2025 to $238.9 million at March 31, 2026, driven by net IPO proceeds of approximately $156.5 million.
- Expense Growth: Total operating expenses increased 108% year-over-year. G&A expenses surged 401% primarily due to increased headcount and professional services associated with becoming a public company. R&D expenses increased 41% due to Phase 3 trial enrollment.
- Capital Structure: The Company transitioned from a private entity with $204.5 million in redeemable convertible preferred stock to a public company with 33.4 million shares of common stock outstanding. No preferred stock remains outstanding.
- Interest Income: Interest income rose to $1.6 million from $0.1 million in the prior year due to higher cash balances and investment yields.
Guidance, Outlook, and Risks
- Clinical Outlook: The Company initiated two registrational Phase 3 trials for the BIM-IOL System in July 2025. Enrollment is expected to complete in 2027, with a planned 505(b)(2) New Drug Application (NDA) submission to the FDA in 2028.
- Liquidity Runway: Management believes existing cash, cash equivalents, and short-term investments ($251.0 million total) are sufficient to fund operations through 2028.
- Internal Controls: The Company identified a material weakness in internal control over financial reporting related to insufficient personnel, lack of risk assessment processes, and segregation of duties. Remediation efforts are underway.
- Legal Proceedings: Glaukos Corporation filed a lawsuit in September 2025 alleging trade secret misappropriation. The Company denies the allegations and has not accrued a loss, deeming it not probable.
- Intellectual Property: The Company relies on a license agreement with the University of Colorado. Risks include potential loss of this license or failure to secure additional IP protection.
Investor Verification Checklist
- Phase 3 Enrollment: Verify the progress and patient enrollment rates of the two registrational Phase 3 trials initiated in July 2025.
- Internal Control Remediation: Monitor the Company's progress in addressing the material weakness in internal controls over financial reporting to ensure future reporting accuracy.
- Legal Litigation: Track developments in the trade secret misappropriation lawsuit filed by Glaukos Corporation.
- Burn Rate: Assess the sustainability of the current operating cash burn rate (~$13.5 million/quarter) against the projected runway through 2028.
- Regulatory Pathway: Confirm the FDA's acceptance of the 505(b)(2) regulatory pathway for the BIM-IOL System.